NORWELL, Mass., Oct. 21, 2026 — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at implementing two patient registries on its established NORD® IAMRARE® platform. This initiative is designed to empower rare disease communities by providing them with the necessary technological infrastructure and organizational support to collect high-quality, patient-reported data directly from individuals and families affected by rare conditions.
Funding for this significant initiative is made possible through the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®), a collaborative agreement established with the Critical Path Institute and funded by the U.S. Food and Drug Administration (FDA). By bridging the gap between patient-driven data collection and regulatory-grade analytics, the program aims to accelerate the understanding and characterization of rare diseases, ultimately supporting the pathway toward new treatments and therapies.
The announcement represents the latest expansion of NORD’s ongoing commitment to supporting rare disease non-profit organizations and patient advocacy groups. Independent research studies and registries led directly by rare disease communities serve as vital reservoirs of real-world evidence. Insights derived from studies hosted on the IAMRARE platform have historically played a crucial role in shaping the rare disease landscape. These contributions include the development of standardized clinical outcome assessments, updates to clinical treatment guidelines, and even evidence supporting at least one major FDA approval.
“This opportunity builds on NORD’s work supporting rare disease nonprofits,” says Tracey Sikora, Vice President of Research and Clinical Programs at NORD. “Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval.”
Under the terms of the new funding opportunity, successful applicants will collaborate closely with NORD starting in April 2027 to conceptualize, build, and launch a dedicated patient registry tailored to their specific rare disease community. The comprehensive support provided by NORD extends far beyond simple software hosting. NORD will construct and maintain the customized registry website and deliver essential training to the registry sponsors.
Furthermore, NORD will guide the selected organizations through every phase of registry establishment. This collaborative framework assists sponsors as they form a registry advisory board, design a rigorous study protocol, construct and tailor participant surveys, navigate the complex Institutional Review Board (IRB) approval process, and establish clear, ethical criteria for sharing the collected data with broader academic and industry researchers.
The application process is officially open, providing a critical window for eligible organizations to apply for this specialized support. The deadline for submitting applications is January 10, 2027. Following a comprehensive review period, accepted applicants will be formally notified by February 1, 2027, setting the stage for formal registry implementation to begin in April 2027. Interested organizations can access the application portal online, while any technical or procedural inquiries regarding the request for applications can be directed to NORD’s designated support team via email.
The NORD IAMRARE Platform has long served as a foundational digital infrastructure for the rare disease community. To date, the platform proudly hosts more than 55 live registries sponsored entirely by patient advocacy organizations. These registries are specifically designed to capture patient-reported data, ensuring that the lived experiences and health trajectories of individuals with rare conditions are accurately recorded and utilized for scientific advancement.
The Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP), which provides the funding for this initiative, functions as an FDA-sponsored initiative intended to offer a centralized, standardized infrastructure. By aggregating diverse data sources, RDCA-DAP supports and accelerates rare disease characterization, fostering an environment where therapy development can proceed more efficiently and with greater precision.
Founded in 1983, the National Organization for Rare Disorders (NORD®) operates as a leading independent, nonpartisan nonprofit organization dedicated to improving the health, well-being, and long-term outlook for more than 30 million Americans living with rare diseases. NORD achieves its mission through a broad coalition of over 350 disease-specific member patient organizations. Additionally, the organization collaborates closely with 49 designated NORD Rare Disease Centers of Excellence, spanning more than 170 academic medical centers, research institutions, and children’s hospitals nationwide. Through these extensive networks, NORD consistently advances clinical care, scientific research, public education, and legislative advocacy to create a better future for every individual and family impacted by a rare condition.
